Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

BACKGROUND: This study assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of the first-in-class dual mammalian target of rapamycin complex (mTORC)1/mTORC2 inhibitor, AZD8055. METHODS: Patients with advanced solid malignancies or lymphomas were recruited into this phase I, open-...

詳細記述

保存先:
書誌詳細
主要な著者: Naing, A, Aghajanian, C, Raymond, E, Olmos, D, Schwartz, G, Oelmann, E, Grinsted, L, Burke, W, Taylor, R, Kaye, S, Kurzrock, R, Banerji, U
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group 2012
主題:
Translational Therapeutics
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3461162/
https://ncbi.nlm.nih.gov/pubmed/22935583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.368
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料